LeMaitre Vascular (NasdaqGM:LMAT) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsDanny Stauder - Director of Equity ResearchDave Roberts - PresidentDorian LeBlanc - CFOGeorge LeMaitre - CEORick Wise - Managing DirectorConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJim Sidoti - AnalystKyle Bauser - Managing Director and Senior Research AnalystMichael Petusky - Managing Director and Senior Investment AnalystMichael Sarcone - Equity AnalystNone - Analy ...

LeMaitre Vascular (NasdaqGM:LMAT) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsDanny Stauder - Director of Equity ResearchDave Roberts - PresidentDorian LeBlanc - CFOGeorge LeMaitre - CEORick Wise - Managing DirectorConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJim Sidoti - AnalystKyle Bauser - Managing Director and Senior Research AnalystMichael Petusky - Managing Director and Senior Investment AnalystMichael Sarcone - Equity AnalystNone - Analy ...

LeMaitre Vascular (NasdaqGM:LMAT) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Speaker8Welcome to the LeMaitre Vascular Q4 2025 financial results conference call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, the Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir.Speaker2Thank you. Good afternoon, and thank you for joining us on our Q4 2025 conference call. With me on today's call is our CEO, George LeMaitre, and ...

Exhibit 99.1 LeMaitre Q4 2025 Financial Results BURLINGTON, MA, February 25, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average sellin ...

BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drov ...

BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to acces ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns. However, identifying such stocks can be challenging due to inherent volatility and risks associated with growth stocks [1]. Group 1: Company Overview - LeMaitre Vascular (LMAT) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2]. - The company has a historical EPS growth rate of 14.3%, with projected EPS growth of 30.1% for the current year, significantly outperforming the industry average of 12% [5]. Group 2: Financial Performance - LeMaitre's year-over-year cash flow growth stands at 35.1%, well above the industry average of 3.4%, indicating strong financial health and capacity for new projects [6]. - The company's annualized cash flow growth rate over the past 3-5 years is 18.1%, compared to the industry average of 8.5%, showcasing consistent performance [7]. Group 3: Earnings Estimates - The current-year earnings estimates for LeMaitre have been revised upward, with the Zacks Consensus Estimate increasing by 4.1% over the past month, reflecting positive market sentiment [9]. - LeMaitre has achieved a Zacks Rank of 2 (Buy) and a Growth Score of B, indicating its potential as a solid choice for growth investors [11].

Core Viewpoint - LeMaitre Vascular, Inc. is actively engaging with investors through participation in three upcoming healthcare conferences, highlighting its commitment to investor relations and market presence [1]. Company Participation in Conferences - LeMaitre Vascular will present at the following investor conferences: - Jefferies London Healthcare Conference on November 18, 2025, with CFO Dorian LeBlanc presenting at 8:00 AM GMT [2]. - Wolfe Research 7th Annual Healthcare Conference on November 19, 2025, with President David Roberts presenting at 10:40 AM ET [2]. - Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, with CFO Dorian LeBlanc presenting at 3:20 PM ET [2]. Company Overview - LeMaitre Vascular specializes in devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally [2]. - The company develops, manufactures, and markets both disposable and implantable vascular devices tailored for vascular surgeons [2].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging due to associated risks and volatility [1] Group 1: Company Overview - LeMaitre Vascular (LMAT) is identified as a promising growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 14.3%, with projected EPS growth of 28.4% this year, significantly surpassing the industry average of 13% [5] Group 2: Financial Metrics - LeMaitre's year-over-year cash flow growth stands at 35.1%, well above the industry average of 1.8%, indicating strong financial health [6] - The company's annualized cash flow growth rate over the past 3-5 years is 18.1%, compared to the industry average of 8.2% [7] Group 3: Earnings Estimates - There is a positive trend in earnings estimate revisions for LeMaitre, with the current-year earnings estimates increasing by 4.1% over the past month [8] - The combination of a Growth Score of B and a Zacks Rank 2 positions LeMaitre favorably for potential outperformance in the market [10]

Core Insights - LeMaitre Vascular (NASDAQ:LMAT) reported Q3 CY2025 revenue of $61.05 million, which was 11.4% higher year-on-year but fell short of Wall Street expectations by 2% [1][6] - The company provided Q4 revenue guidance of $62.8 million, which is 2.9% below analyst estimates [1][6] - GAAP EPS was $0.75, exceeding analysts' consensus by 31.5% [1][6] Revenue Performance - Q3 revenue of $61.05 million compared to analyst estimates of $62.3 million, marking an 11.4% year-on-year growth [6] - Organic revenue growth was 12% year-on-year, below the expected 14.8% [6] - Adjusted EBITDA was $18.99 million, with a margin of 31.1%, surpassing analyst expectations [6] Management Commentary - Management highlighted strong performances from Grafts and Shunts product lines, attributing organic sales growth primarily to price increases rather than unit volume [3][5] - CEO George LeMaitre noted that a catheter recall earlier in the year led to some customers pulling forward purchases, which may limit growth in Q3 and Q4 [3][4] - The company is facing challenges in the Asia-Pacific region due to management turnover and market dynamics [4][5] Future Outlook - Management's guidance for Q4 reflects tempered expectations, citing near-term headwinds including the ongoing impact of the catheter recall and foreign currency fluctuations [4] - Investments in new distribution centers and hiring remain priorities, with a focus on biologics and niche products where pricing power is strongest [4]